These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15694409)

  • 1. Alternative bisphosphonate targets and mechanisms of action.
    Bukowski JF; Dascher CC; Das H
    Biochem Biophys Res Commun; 2005 Mar; 328(3):746-50. PubMed ID: 15694409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
    Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
    Kellinsalmi M; Mönkkönen H; Mönkkönen J; Leskelä HV; Parikka V; Hämäläinen M; Lehenkari P
    Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
    Kanakis I; Kousidou OCh; Karamanos NK
    In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bisphosphonates and bone metastases of solid tumors: therapeutic interest despite its anti-resorptive properties].
    Clézardin P
    Prog Urol; 2003 Apr; 13(2 Suppl 1):28-35. PubMed ID: 12815807
    [No Abstract]   [Full Text] [Related]  

  • 6. [Long-term bisphosphonate administration and its effect on bone metabolism].
    Hagino H
    Clin Calcium; 2005 Apr; 15(4):643-7. PubMed ID: 15802778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of alpha-hydroxydimethyl-gamma-aminopropylidene bisphosphonate on the bone tissue of rats during hypokinesia].
    Shvets VN; Pankova AS
    Kosm Biol Aviakosm Med; 1989; 23(1):27-31. PubMed ID: 2709747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanisms for anti-resorptive action of bisphosphonates in bone diseases].
    Bałczewska E; Bałczewski P
    Postepy Biochem; 2001; 47(4):328-36. PubMed ID: 12046265
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
    Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
    J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
    Väänänen K
    Adv Drug Deliv Rev; 2005 May; 57(7):959-71. PubMed ID: 15876398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer therapies for osteoporosis.
    Palaniswamy C; Selvaraj DR; Rao V; Patel U
    Am J Ther; 2010; 17(2):197-200. PubMed ID: 20305400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
    Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
    Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro.
    Faucheux C; Verron E; Soueidan A; Josse S; Arshad MD; Janvier P; Pilet P; Bouler JM; Bujoli B; Guicheux J
    J Biomed Mater Res A; 2009 Apr; 89(1):46-56. PubMed ID: 18404716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Melatonin and bone status].
    Ostrowska Z; Wołkowska-Pokrywa K; Kos-Kudła B; Swietochowska E; Marek B; Kajdaniuk D
    Pol Merkur Lekarski; 2006 Oct; 21(124):389-93. PubMed ID: 17205785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
    Clézardin P
    Bone; 2011 Jan; 48(1):71-9. PubMed ID: 20655399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.
    Plotkin LI; Manolagas SC; Bellido T
    Bone; 2006 Sep; 39(3):443-52. PubMed ID: 16627025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoimmunology--the hidden immune regulation of bone.
    Caetano-Lopes J; Canhão H; Fonseca JE
    Autoimmun Rev; 2009 Jan; 8(3):250-5. PubMed ID: 18722561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic breast cancer induces an osteoblast inflammatory response.
    Kinder M; Chislock E; Bussard KM; Shuman L; Mastro AM
    Exp Cell Res; 2008 Jan; 314(1):173-83. PubMed ID: 17976581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates and connexin 43: a critical review of evidence.
    Sadr-Eshkevari P; Ashnagar S; Rashad A; Dietz M; Jackowski J; Abdulazim A; Prochnow N
    Cell Commun Adhes; 2014 Oct; 21(5):241-7. PubMed ID: 24946183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.